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Phytanic acid and pristanic acid are derived
containing a methyl group in the third position is
from phytol, which enter the body via the
first converted to a 2-methyl branched fatty acid,
diet. Phytanic acid contains a methyl group in
pristanic acid, via a-oxidation (2), which can
position three and therefore cannot undergo
then undergo b-oxidation as outlined in Figure 1.
b-oxidation directly, but instead must first
Before a-oxidation can take place, the phytanic
undergo a-oxidation to pristanic acid, which
acid is activated to the CoA ester, which can
then enters b-oxidation. Both these pathways
occur either outside the peroxisome by the longoccur in peroxisomes, and in this study we
chain acyl-CoA synthetase or inside the
have identified a novel peroxisomal acyl-CoA
peroxisome by the very long-chain acyl-CoA
thioesterase, named ACOT6, which we show
synthetase (3,4).
is specifically involved in phytanic acid and
a-Oxidation consists of three steps where the
pristanic acid metabolism. Sequence analysis
phytanoyl-CoA is hydroxylated into 2of ACOT6 revealed a putative peroxisomal
hydroxyphytanoyl-CoA by phytanoyl-CoA 2targeting signal at the C-terminal end, and
hydroxylase (PHYH) in the first step. In the
cellular localization experiments verified it as
second step, formyl-CoA is cleaved off by the 2a peroxisomal enzyme. Subcellular
hydroxyphytanoyl-CoA lyase, forming pristanal.
fractionation experiments showed that
The formyl-CoA produced is hydrolyzed into
peroxisomes contain by far the highest
formate and oxidized to CO2 in the cytosol. In
phytanoyl-CoA/pristanoyl-CoA thioesterase
the third and last step of a-oxidation pristanal is
activity in the cell, which could be almost
converted into pristanic acid by an aldehyde
completely immunoprecipitated using an
dehydrogenase (5).
ACOT6 antibody. Acot6 mRNA was mainly
The 2-methyl branched pristanoyl-CoA formed
expressed in white adipose tissue and was coby a-oxidation, or indeed pristanic acid directly
expressed in tissues with A c o x 3 (the
ingested via the diet, is naturally present in two
pristanoyl-CoA oxidase). Furthermore, Acot6
stereoisomers, 2R and 2S, where the
was identified as a target gene of the PPARa
peroxisomal pristanoyl-CoA oxidase (ACOX3)
and is upregulated in mouse liver in a PPARa
is specific for the S-stereoisomer. Therefore the
dependent manner.
2R-pristanic acid must first undergo
Methyl branched fatty acids such as phytanic
isomerization into the 2S-form, which then
acid (3,7,11,15-tetramethylhexadecanoic acid)
undergoes b-oxidation. This racemization step is
and
pristanic
acid
(2,6,10,14carried out by the 2-methylacyl-CoA racemase
tetramethylpentadecanoic acid) are found in
(AMACR) (6,7). The first step in b-oxidation of
ruminant fats, such as dairy products and beef,
pristanic acid is the oxidation by ACOX3, and
but are also found in chlorophyll-containing
the two subsequent steps, hydration and
plants and are ingested in the diet. The body
dehydrogenation, are catalyzed by
cannot metabolize chlorophyll itself, but instead
multifunctional protein-2 (MFP-2), with the last
intestinal flora, mainly present in ruminant
step, the thiolytic cleavage, carried out by sterol
animals, can cleave off the side chain of
carrier protein x (SCPx), with the release of
chlorophyll, producing phytol. Phytol is then
propionyl-CoA in the first and third cycle of bconverted to phytanic acid or phytanoyl-CoA
oxidation (for review see (8)). After three rounds
depending on if the phytol is metabolized further
of b-oxidation 4,8-dimethylnonanoyl-CoA
directly in the intestine or after uptake into cells,
(DMN-CoA) is produced, which can then either
respectively (for review see (1)). Phytanic acid
be hydrolyzed to the free acid, or esterified to

carnitine for transport to mitochondria for further
b-oxidation (9,10). These pathways are well
described in the literature, however, subcellular
localization, activation and transport of
substrates and products are still somewhat
unclear. Both a-oxidation and the first three
cycles of b-oxidation are entirely peroxisomal
processes (8,11,12), with the possible exception
of the last step of a-oxidation argued to take
place either in the ER or peroxisomes (5,13).
The importance of a-oxidation and b-oxidation
are underscored by the diseases affecting either
of the pathways, such as Refsum’s disease,
AMACR deficiency and MFP-2 deficiency (for
reviews see (8,14)). Also the importance of the
breakdown of phytol to phytanic acid is
demonstrated by the occurrence of a disease
affecting the microsomal fatty aldehyde
dehydrogenase (FALDH) catalyzing the
oxidation of phytenal to phytenic acid, causing
the Sjögren-Larsson syndrome (15).
In this paper we describe the identification of a
novel gene that encodes a peroxisomal acyl-CoA
thioesterase specific for phytanoyl-CoA and
pristanoyl-CoA, which can hydrolyze these
compounds to phytanic acid, pristanic acid and
coenzyme A. This phytanoyl-CoA/pristanoylCoA thioesterase (Acot6) gene is a member of a
gene family of acyl-CoA thioesterases, localized
in a condensed cluster on chromosome 12 D3 in
mouse, which code for acyl-CoA thioesterases
with localizations in cytosol, mitochondria and
peroxisomes (16-18).
MATERIALS AND METHODS
Localization of ACOT6 in peroxisomes- The fulllength open reading frame encoding ACOT6 was
amplified by RT-PCR from mouse kidney using
the following primers 5’- CAT ATG GCG GCG
ACA CTG A -3’ and 5’- CAT ATG TTA CAG
TTT GCT GTG -3’ (Cybergene AB, Huddinge,
Sweden). The product was cloned into the
pcDNA3.1/NT-GFP vector (Invitrogen Corp.,
Carlsbad, CA), which expresses the protein as an
N-terminal green fluorescent fusion protein,
leaving the C-terminal –SKL of ACOT6
accessible. The construct was transfected into
human skin fibroblasts from a control subject
and a Zellweger patient using the calcium
phosphate method. Immunofluorescence
microscopy was carried out as described
previously (19).

Chemical synthesis of pristanoyl-CoA and
phytanoyl-CoA- Phytanoyl-CoA and pristanoylCoA were synthesized chemically from the
respective free acids (Sigma-Aldrich Inc., St.
Louis, MO) by first forming the anhydride and
in the next step the CoA ester (20). PhytanoylCoA and pristanoyl-CoA were then purified by
reversed phase high performance liquid
chromatography using a C18 Ultrasphere ODS
5mm (4.6 ¥ 250 mm) column (Beckman Coulter,
Inc., Fullerton, CA), with a mobile phase
containing 50 mM potassium phosphate buffer,
pH 5.4, and 38% isopropanol. After 10 min the
mobile phase was changed to 58% isopropanol
for 40 min. Purified products were then verified
by mass spectrometry as described in (18).
Expression of recombinant ACOT6 protein- The
full-length open reading frame for Acot6 was
amplified by RT-PCR from mouse kidney using
the One-Step RNA PCR kit (Takara
Biomedicals, Shiga, Japan), using the following
primers: 5’- GAA TTC ATG GCG GCG ACA
CTG AGC G -3’ and 5’- GTC GAC TTA CAG
TTT GCT GTG CCT G -3’ (Cybergene AB,
Huddinge, Sweden). The addition of an EcoRI
and a SalI site (indicated in bold) were used for
cloning into the pMAL-C2x vector (New
England Biolabs, Beverly, MA), which results in
expression of the protein as a fusion protein with
maltose binding protein. The construct was
transformed into BL21(DES3) pLysS (Novagen
Inc., Madison, WI) and protein expression was
induced by the addition of 0.3 mM isopropyl-bD-galactopyranoside (Sigma-Aldrich Inc., St.
Louis, MO) for 2 h at 37°C in LB-media
supplemented with 2% glucose, 50 m g / m l
ampicillin and 34 m g/ml chloramphenicol.
Bacteria were harvested by centrifugation at
5000 ¥ g for 10 min, washed with 20 mM TrisHCl pH 7.4 and frozen overnight in 50 ml of
column buffer (20 mM Tris, 200 mM NaCl and
1 mM EDTA, pH 7.4). Bacteria were lyzed by
sonication for 1 min at 5s intervals and
centrifuged at 16 000¥ g for 30 min.
Recombinant protein was purified by affinity
chromatography using amylose resin (New
England Biolabs, Beverly, MA), by elution with
10 mM maltose in column buffer. Purity and size
of the eluted protein was checked by SDS-PAGE
and Coomassie brilliant blue staining, and
protein concentration was determined using the
Bradford assay (21).
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Measurement of acyl-CoA thioesterase activityAcyl-CoA thioesterase activity was measured
spectrophotometrically at 232 nm in phosphate
buffered saline (PBS) pH 7.4, measuring the
cleavage of the thioester bond as a decrease in
the absorbance. Various acyl-CoAs were used as
substrates, including acetyl-CoA, propionylCoA, acetoacetyl-CoA, butyryl-CoA, heptanoylCoA, decanoyl-CoA, lauroyl-CoA, myristoylCoA, palmitoyl-CoA, palmitoleoyl-CoA, oleoylCoA,
l i n o l e o y l - C o A , linolenoyl-CoA,
arachidoyl-CoA, arachidonoyl-CoA, behenoylCoA, branched-chain substrates including
pristanoyl-CoA, phytanoyl-CoA, DMN-CoA, 2methyloctadecanoyl-CoA, the bile acid
intermediate trihydroxycholoyl-CoA and the
primary bile acid choloyl-CoA. The pristanoylCoA, phytanoyl-CoA, trihydroxycholoyl-CoA
and choloyl-CoA were synthesized in our lab,
while 4,8-dimethylnonanoyl-CoA, behenoylCoA and an aliquot of phytanoyl-CoA were a
kind gift from Dr Ronald Wanders. The other
acyl-CoAs were obtained from Sigma-Aldrich
Inc., St. Louis, MO. The effect of free CoASH
on ACOT6 activity was tested at concentrations
up to 500 mM. The kinetic parameters were
calculated using Prism Enzyme Kinetics
program, using an extinction coefficient of
E232=4.25 mM-1cm-1 to calculate the specific
activities.
Subcellular fractionation and isolation of
peroxisomes- For subcellular fractionation
experiments, adult male mice on a pure C57Bl6
background (Jackson Laboratories, Maine, USA)
were used. Mice were fed either a normal chow
diet or a diet containing 0.5% (w/w) clofibrate
(ICI Pharmaceuticals, Macclesfield, Cheshire,
U.K.) for 1 week and all mice were fasted
overnight before sacrifice. Following sacrifice
by CO2 asphyxiation and cervical dislocation,
liver and kidneys were excised and used directly
for subcellular fractionation. Tissues were
weighed and placed in ice-cold buffer containing
0.25 M sucrose, 1 mM EDTA, 15 mM MES, pH
6.5, minced finely, homogenized and diluted to a
10% homogenate. Homogenates were
centrifuged for 10 min at 500¥gav and pellets
were re-homogenized and re-centrifuged. Postnuclear supernatants were combined and
centrifuged at 4000¥g av for 10 min to sediment
mitochondria, which were saved for subsequent
measurements. The supernatants were
centrifuged at 30 000¥g av for 20 min to obtain

the light mitochondrial fraction containing the
bulk of peroxisomes. The pellets were washed
once by centrifugation and finally dissolved in
ice-cold 0.25 M sucrose and 15 mM Hepes pH
7.4. These fractions were then layered on top of
linear 20-45% Optiprep (Sigma-Aldrich Inc., St.
Louis, MO) gradients, resting on a 50% Optiprep
cushion, and centrifuged for 90 min at 40
000¥gav in a fixed angle rotor and 1 ml fractions
were collected from the bottom of the gradient.
The fractions were analyzed for the peroxisomal
marker catalase as described in (22).
Supernatants obtained after preparation of the
light-mitochondrial fractions were centrifuged at
40 000¥gav for 2h and supernatants were saved
as cytosolic fractions and pellets were dissolved
in 0.25 M sucrose and 15 mM Hepes, pH 7.4,
and saved as microsomal fractions for
subsequent measurements.
Immunoprecipitation of ACOT6 in purified
peroxisomes- ACOT6 anti-sera were produced in
rabbits immunized with a peptide with the
following sequence: CQKYLNGEKPARH,
which corresponds to amino acids 406-417 of
the ACOT6 protein and a C-terminal Cys for
coupling of the peptide to Keyhole Limpet
Haemocyanin (KLH). The antibody was affinity
purified by chromatography as described
previously (17). Pre-immune serum or affinity
purified ACOT6 antibody in various
concentrations (in PBS/0.1% Triton) was added
to Protein A sepharose beads and incubated at
4°C overnight. The protein A sepharose
suspension was centrifuged at 10 000¥gav in a
microfuge for 10 min, the supernatants were
removed and 100 mg of peroxisomal protein in
PBS/0.1% Triton was added and incubated for 2
h at 4°C in an orbital shaker. The protein A
sepharose suspension was spun down and the
supernatants were used for acyl-CoA
thioesterase activity measurements as described
above.
Animals and treatments for investigation of
tissue expression and regulation of expressionAdult male wild-type (+/+) mice or PPARa-null
(-/-) mice on a pure Sv/129 genetic background
(23) (kindly provided by Dr. Frank Gonzalez and
Dr. Jeffrey Peters) were used for RNA isolation
and for preparation of protein homogenates.
Mice were fed either a standard chow diet or a
diet containing 0.1% Wy-14,643 (CalbiochemNovabiochem International, La Jolla, CA) for 1
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week before sacrifice. Mice were sacrificed by
CO2 asphyxiation and cervical dislocation and
tissues were excised, frozen in liquid nitrogen
and stored at –70oC.
Isolation of total RNA and Real-Time-PCR (QPCR)- Total RNA from various mouse tissues
was isolated using TRIzol Reagent (Invitrogen
Corp., Carlsbad, CA) and was DNase treated
using RQ1 RNase-Free DNase (Promega Corp.,
Madison, WI). The quality of the RNA was
checked on a 1% agarose-formaldehyde gel.
Tissue expression was investigated in liver,
kidney, heart, lung, spleen, brain, proximal (first
10 cm of small intestine) and distal intestine (last
10 cm of small intestine), brown adipose tissue
and white adipose tissue using total RNA pooled
from three individual animals. For regulation by
Wy-14,643 treatment in liver, three individual
animals in each group were used. Synthesis of
cDNA was performed with 1 mg of total RNA
using TaqMan reverse transcription reagents
(Applied Biosystems, Foster city, CA). For
Acot6, a specific amplicon was designed using
the Primer Express Software spanning over the
exon 2/exon 3 boundary using the following
primers: 5’-ACG CCA TCC TCA GGT GAA
AG-3’ and 5’-TCA GGA AAG CAG CCA TCG
A-3’, and a probe with a 5’-FAM and 3’-dabcyl
with the following sequence 5’-TGT CTC CAA
AGG TGC TGA TCT GTG CC-3’. Q-PCR was
performed in single-plex and in triplicate with
18S as an endogenous control as described
previously (18). For tissue expression of Phyh,
A m a c r and A c o x 3, SYBRgreen (Applied
Biosystems, Foster city, CA) was used, as well
as for Acot6 in the comparative tissue expression
experiment. Specific primers for Phyh were
designed over the exon 4/exon 5 boundary, for
Amacr over the exon2/exon3 boundary and for
Acox3 over the exon 5/exon 6 boundary, using
the primers shown in Table I. As an endogenous
control, a specific amplicon of mouse
hypoxanthine guanine phosphoribosyl
transferase (H p r t 1 ) spanning over the
exon6/exon7 boundary was used, with primers
also shown in Table I. Q-PCR was run as
described in (18) with the change of master mix
to SYBRgreen Power master mix (Applied
Biosystems, Foster City, CA) and with addition
of a dissociation step to check the specificity of
the products. The PCR products were checked
by agarose gel electrophoresis. The efficacy of
all primer pairs was checked by running Q-PCR
on dilutions of the template cDNA, verifying

that tissue expression was analyzed in the linear
range of the PCR. The average threshold (CT)
values per triplicate were used to calculate the
relative amounts of mRNA using the 2-DDCT
method according to Applied Biosystems
guidelines.
Western blot analysis- Liver homogenates were
prepared from control and Wy-treated male
mouse, and 50 mg of protein was used for SDSPAGE and Western blotting as described
previously (24). ACOT6 antibody was produced
and purified as described above, and the
antibody reactivity was checked against
recombinant ACOT6 protein.
RESULTS
Identification of ACOT6 as a novel peroxisomal
acyl-CoA thioesterase- We have previously
identified a cluster of genes on mouse
chromosome 12 D3, which codes for acyl-CoA
thioesterases. To date we have characterized 5 of
these genes, named Acot1-5. Acot3, Acot1 and
Acot2 encode long-chain acyl-CoA thioesterases
localized in peroxisomes, cytosol and
mitochondria, respectively (17,25,26). Acot5 and
A c o t 4 encode a medium-chain acyl-CoA
thioesterase and a succinyl-CoA thioesterase,
respectively (17,18). This cluster contains a
further gene, named Acot6, which shows an
identical gene organization to the other genes in
this cluster. Based on the genomic sequence,
primers were designed to amplify the open
reading frame of Acot6 by PCR and the product
was completely sequenced and deposited under
Accession Number AY999300. The resulting
protein contains 419 amino acids, with a
calculated molecular mass of 46.7 kDa and
shows approximately 70% sequence identity to
the other ACOTs in this gene family. Notably
the C-terminal ends serine, lysine, leucine (SKL), strongly suggesting a peroxisomal
localization. To examine whether this –SKL
results in targeting of the protein to peroxisomes,
we expressed the protein as an N-terminal fusion
protein with green fluorescent protein (GFP),
leaving the C-terminal -SKL accessible. The
Acot6-GFP plasmid was transfected into human
skin fibroblasts and showed a punctate
expression indicative of a peroxisomal
localization (Fig. 2A). A peroxisomal
localization was then confirmed by transfection
of the same plasmid into fibroblasts from a
Zellweger patient. These fibroblasts lack
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functional peroxisomes since they have a
generalized import defect, and in these cells
ACOT6-GFP expression showed a diffuse
cytosolic localization (Fig. 2B), confirming that
the punctate expression visible in the control
fibroblasts is indeed peroxisomal.
Identification of ACOT6 as a peroxisomal
phytanoyl-CoA/pristanoyl-CoA thioesteraseExpression of ACOT6 as a fusion protein with a
histidine tag or as a fusion protein with
thioredoxin failed to produce soluble protein.
However, expression of ACOT6 as a fusion
protein with maltose binding protein resulted in
soluble protein. After purification by affinity
chromatography using an amylose resin, acylCoA thioesterase activity was measured on a
variety of acyl-CoAs (see MATERIALS AND
METHODS), which showed ACOT6 to be
active only on pristanoyl-CoA (2,6,10,14tetramethylpentadecanoyl-CoA) with a Vmax of
3.20 mmol/min/mg and a Km of 24 mM (Fig. 3).
The enzyme was not active on any other methyl
branched substrates, i.e. 2-methyloctadecanoylCoA and DMN-CoA, although at this stage
phytanoyl-CoA was not available, demonstrating
that ACOT6 is highly specific for pristanoylCoA. The 2-methyl group in pristanic acid is
present in both the 2R and 2S configuration, and
it has been shown that the peroxisomal
pristanoyl-CoA oxidase (ACOX3) is only active
on the 2S-stereoisomer (8). Therefore the amethylacyl-CoA racemase (AMACR) is required
as an auxiliary enzyme for complete oxidation of
pristanic acid (6). Since the commercial pristanic
acid was chemically synthesized, it is presumed
to contain a racemic mixture of 2R and 2S
stereoisomers. We therefore tested if ACOT6
was active on both stereoisomers by incubation
of ACOT6 with the presumed racemic mixture
of synthesized pristanoyl-CoA for 30 min, and
results showed that ACOT6 hydrolyzed almost
100% of the added substrate, suggesting that
ACOT6 has no stereo-specificity for the 2R and
2S isomers (data not shown). Increasing
concentrations of free CoASH up to 500 mM
showed that ACOT6 activity is not regulated by
free CoASH (data not shown), similar to the
other members of this gene family.
Even using the maltose binding protein
expression system it was very difficult to obtain
active ACOT6 protein, probably due to improper
folding. In order to verify that ACOT6 is indeed

a peroxisomal pristanoyl-CoA thioesterase, we
also performed complementary experiments
utilizing purified peroxisomes from mouse liver
and kidney from control and clofibrate treated
animals. Peroxisomes were isolated using
standard procedures with the final step being
gradient centrifugation in Optiprep. When
performing the biochemical characterization of
recombinant ACOT6 (described in Fig. 3), we
did not have access to phytanoyl-CoA, which is
not commercially available. Based on the
structural similarity to pristanoyl-CoA, we
therefore subsequently synthesized phytanoylCoA and tested the activity in the purified
organelle fractions. Indeed, the activity in
purified peroxisomes is very similar with
phytanoyl-CoA and pristanoyl-CoA, with Km
values of 32 and 35 mM and Vmax values of 176
and 215 nmol/min/mg, respectively, suggesting
that ACOT6 could be similarly active on both
these substrates (Fig. 4A-B). To establish
whether the peroxisomal phytanoyl-CoA and
pristanoyl-CoA thioesterase activities in
peroxisomes are catalyzed by ACOT6, we
immunoprecipitated the peroxisomal fraction
with an ACOT6 peptide antibody, using preimmune serum as a control. The anti-ACOT6
IgG immunoprecipitated almost all of the
peroxisomal phytanoyl-CoA and pristanoyl-CoA
thioesterase activity, demonstrating that ACOT6
is the major phytanoyl-CoA/pristanoyl-CoA
thioesterase in peroxisomes (Fig. 4C). As
expected, no lauroyl-CoA thioesterase activity
was immunoprecipitated with the ACOT6
antibody. Taken together, these data strongly
suggest that ACOT6 is a novel peroxisomal
thioesterase with a function in regulation of
phytanic acid and pristanic acid metabolism.
Phytanoyl-CoA and pristanoyl-CoA thioesterase
activity is highest in peroxisomes- The important
role of peroxisomes in the metabolism of
phytanic acid and pristanic acid has been well
established (for review see (27)). If the
physiological function of ACOT6 is to regulate
phytanic acid and pristanic acid levels, we would
expect the activity to be highest in peroxisomes.
Measurement of phytanoyl-CoA/pristanoyl-CoA
thioesterase activity in different subcellular
fractions showed that this is indeed the case. The
activity in the peroxisomal fractions was 60-70
nmol/min/mg protein, while the activity was
only 3-11 nmol/min/mg protein in the cytosolic,
mitochondrial and microsomal fractions (Fig. 5).
In addition, ACOT6 activity appears to be high
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in liver since the thioesterase activity with these
substrates is about double as high as the
thioesterase activity with lauroyl-CoA (C12CoA) (Fig. 4C), which in peroxisomes is due to
the combined actions of ACOT3, ACOT5 and
ACOT8 (17,19).
Expression of Acot6 mRNA, protein and activity
is increased via the peroxisome proliferatoractivated receptor alpha (PPARa)- Peroxisomes
from liver and kidney were isolated from control
and clofibrate treated mice, and comparison of
the activity between peroxisomes from liver and
kidney showed that kidney peroxisomes contain
2-3 times higher activity with lauroyl-CoA,
phytanoyl-CoA and pristanoyl-CoA than liver
peroxisomes (Fig. 6A). Clofibrate treatment did
not change the specific activity to any noticeable
extent, suggesting that the expression of ACOT6
is induced by the clofibrate treatment in parallel
with peroxisome proliferation. The expression of
many genes involved in peroxisomal b oxidation, as well as all the other members of
this thioesterase family, are regulated via the
PPARa. We therefore investigated the regulation
of A c o t 6 at mRNA and protein level by
treatment of wild type and PPARa-null mice
with the peroxisome proliferator Wy-14,643. QPCR on liver RNA from male mice treated with
Wy-14,643 showed that Acot6 mRNA is highly
upregulated (about 11-fold) in liver in a PPARa
dependent manner (Fig. 6B). We also
investigated the regulation of ACOT6 in liver at
protein level using Western blotting, which also
showed a strong upregulation of ACOT6 in a
P P A R a dependent manner (Fig. 6C).
Peroxisome proliferation is evident in mouse
liver after treatment with peroxisome
proliferators, which has been reported to
increase the cytoplasmic area of peroxisomes
about 5-8 fold (28,29). The magnitude of the
increased expression of ACOT6 is therefore
compatible with the activity data showing that
the treatment increases the expression in parallel
with peroxisome proliferation and thereby
maintains a similar specific activity in
peroxisomes after proliferation by fibrate
treatment.
Tissue expression profiling shows that Acot6 is
co-expressed with Acox3 Q-PCR analysis of
mRNA levels was used to establish the tissue
expression of Acot6. The data showed that Acot6
mRNA is most highly expressed in white

adipose tissue, followed by kidney, liver, brown
adipose tissue and brain (Fig. 7A). The
identification of a specific phytanoylCoA/pristanoyl-CoA thioesterase with high
expression in white adipose tissue is intriguing,
and we therefore set out to investigate tissue
expression of some other genes involved in the
a-oxidation pathway and branched-chain boxidation pathway. Pristanoyl-CoA oxidase
(Acox3), the first and presumed rate limiting step
in the branched-chain b-oxidation pathway (see
Fig. 1), is also most highly expressed in white
adipose tissue, and the expression pattern closely
resembles the expression pattern of Acot6 (Fig.
7B). The first step in the a-oxidation pathway is
catalyzed by phytanoyl-CoA 2-hydroxylase
(PHYH), and Q-PCR showed that Phyh mRNA
is widely expressed with highest expression in
brown adipose tissue and liver, and only low
expression in lung, spleen and brain (Fig. 7C).
The a-methylacyl-CoA racemase (AMACR), the
enzyme that converts the 2R form of pristanoylCoA into the 2S form, is most highly expressed
at mRNA level in liver and kidney, but also
showed a rather similar expression profile to
Phyh (Fig. 7D). The expression analysis thus
revealed that Acot6 and Acox3 show similar
tissue expression profiles with both genes being
most highly expressed in white adipose tissue,
and that P h y h and Amacr also show similar
expression profiles to each other, although
different expression compared to Acot6 and
Acox3.
In an inter-tissue mRNA analysis, a few selected
tissues were analyzed by Q-PCR in parallel
using SYBRgreen probes for Acot6, Acox3,
Amacr and Phyh. Since primer efficacy was
confirmed to be 100% for all primer pairs as
described in MATERIALS AND METHODS, it
should be possible to compare expression of
different genes analyzed in parallel. Such QPCR analysis suggest that Phyh mRNA
expression is about 100 times higher in liver than
for the other enzymes (data not shown). Amacr
expression is also much higher than expression
of A c o t 6 and A c o x 3 in liver and kidney.
However, from this analysis it appears that Acot6
and Acox3 may be expressed at very similar
levels in the various tissues, and that Amacr is
expressed at a lower level than Acot6 and Acox3
in white adipose tissue (Fig. 8).
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DISCUSSION
The Acot6 gene is located in a dense cluster of
six genes coding for acyl-CoA thioesterases, of
which five genes have been characterized
previously (17,18,25,26). One gene codes for a
cytosolic thioesterase (Acot1), one gene codes
for a mitochondrial thioesterase (Acot2), and
three genes code for peroxisomal thioesterases
(Acot3-5). Of these thioesterases, only ACOT4
shows a narrow substrate specificity,
hydrolyzing succinyl-CoA, and to a low extent
glutaryl-CoA (18). Here we have characterized
in detail the sixth gene in this cluster, Acot6, and
show that this gene also codes for a peroxisomal
thioesterase, which specifically hydrolyzes the
CoA esters of the methyl-branched fatty acids
phytanic acid and pristanic acid. The
significance of this activity is evident from the
subcellular fractionation experiments, which
showed that phytanoyl-CoA/pristanoyl-CoA
thioesterase activity is clearly highest in
peroxisomes. The data further show that the
activity with these substrates in peroxisomes
isolated from liver and kidney is 2-3 fold higher
than the activity with lauroyl-CoA, a straight
chain acyl-CoA, suggesting that it represents a
major thioesterase activity in peroxisomes.
Immunoprecipitation using an ACOT6 antibody
immunoprecipitated almost all phytanoylCoA/pristanoyl-CoA thioesterase activity, and
taken together these data strongly connect
ACOT6 to metabolism of phytanic and pristanic
acid in peroxisomes. Furthermore, recombinant
ACOT6 showed no activity with saturated or
unsaturated straight-chain acyl-CoAs of varying
chain length, or with other branched-chain
substrates such as DMN-CoA and 2methyloctadecanoyl-CoA, demonstrating that
ACOT6 is apparently specific for phytanoylCoA/pristanoyl-CoA. These data raise the
question of the physiological function of
ACOT6. Elucidation of the metabolism of
phytanic acid during the last few years has
demonstrated the importance of peroxisomes,
which is obvious from the severe elevation in
phytanic acid and pristanic acid seen in various
peroxisomal disorders (30). Branched fatty acids
are widely distributed in foods at low amounts,
where humans typically ingest about 50-100
mg/day (8), of which about 50% is absorbed and
eventually metabolized or stored in triglycerides.
Human plasma contains detectable amounts of
phytanic and pristanic acid (31), and it was also

demonstrated that human and bovine tissues
contain comparable amounts of pristanic acid
and phytanic acid with the highest levels found
in white adipose tissue (32). Studies in rats fed
pristanic acid suggested that about 10% of the
absorbed pristanic acid is still stored after one
week, preferentially in white adipose tissue and
liver (33,34). Therefore, evidently a considerable
amount of the ingested branched fatty acids are
stored in white adipose tissue and liver. Earlier
investigations have suggested a-oxidation and boxidation to occur mainly in liver and kidney
(35-37), which is in line with our data showing
that the expression of some selected genes
involved in these pathways are strongly
expressed in these tissues. However, our data
also show a remarkable co-expression of Acox3
and Acot6 with the highest expression in white
adipose tissue, suggesting a different metabolism
in this tissue. It should be kept in mind that the
a-methyl group in pristanic acid is present in
both the 2R- and 2S- isomers. However, only the
2S-stereoisomer can be degraded via b-oxidation
(38) and therefore racemization becomes an
important step in the b-oxidation of pristanoylCoA, which proceeds for three cycles in
peroxisomes with the formation of DMN-CoA,
as outlined in Fig. 9. DMN-CoA is transferred to
the corresponding carnitine ester by peroxisomal
carnitine octanoyltransferase (CROT) and
transported to the mitochondria for further
degradation to 2,6-dimethylheptanoyl-CoA (39).
Alternatively the DMN-CoA could be
hydrolyzed to free DMN by ACOT8 or ACOT5
for transport out of the peroxisome (10,19).
Interestingly, as shown in Fig. 8 (in which we
have attempted to compare the expression levels
of the Amacr, Acox3 and Acot6), the expression
of the racemase, Amacr, seems to be quite low in
peroxisomes in white adipose tissue, especially
when considering that this enzyme has a dual
localization in peroxisomes and mitochondria
(40). These data may be interpreted in such a
way that the apparently low level of A m a c r
becomes rate limiting in white adipose tissue in
the b-oxidation of branched fatty acids, and
therefore excess 2R-pristanoyl-CoA produced in
white adipose tissue peroxisomes may be
hydrolyzed by ACOT6 (Fig. 9). Hence, ACOT6
may have a function in hydrolyzing 2Rpristanoyl-CoA into 2R-pristanic acid, which can
exit the peroxisome and following activation to
the corresponding CoA-ester be esterified into
triacylglycerols in white adipose tissue, or
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alternatively be transported to, for example, the
liver or kidney for further metabolism. This
hypothesis is also supported by our observation
that ACOT6 does not show selectivity for the 2R
and 2S isomers, which would allow for the
hydrolysis of accumulating 2R-pristanoyl-CoA.
It would therefore be of interest to analyze
triacylglycerols in white adipose tissue for the
relative content of 2R- and 2S-pristanic acid.
Taken together, our data suggest that ACOT6
can function as an auxiliary enzyme in the
oxidation of pristanic acid, promoting temporary
storage of the 2R isomer in white adipose tissue
before being further metabolized in other tissues.
The identification of A cot6 as a novel PPARa
target gene is in line with the previously
described PPARa regulation of all the other
genes of the thioesterase gene cluster, and
suggests a role for PPARa also in the
metabolism of branched-chain lipids. Phytol
feeding in mice has a lipid-lowering effect in
plasma and results in upregulation of genes in
straight-chain b-oxidation, together with the
MFP2 (D-bifunctional protein) and SCPx
involved in branched chain b-oxidation, and the
PHYH involved in a-oxidation, although the
latter enzyme is induced in a PPARa independent manner (41). It would be likely that
Acot6 would also be upregulated by phytol

feeding, via PPARa and would therefore
contribute to the a- and b-oxidation of branched
fatty acids. Both products of the activity of
ACOT6, phytanic acid and pristanic acid, have
previously been shown to function in gene
regulation, probably acting as ligands for nuclear
receptors. In cell experiments pristanic acid and
phytanic acid have been shown to be potent
activators of PPARa and RXRa, respectively
(42,43). Therefore ACOT6 may also function in
recruiting or maintaining ligands for these
nuclear receptors and thereby also be involved in
gene regulation.
In summary we have identified a novel
peroxisomal PPARa regulated phytanoylCoA/pristanoyl-CoA thioesterase in mouse. This
enzyme is most highly expressed in white
adipose tissue, similar to Acox3, the presumed
rate-limiting enzyme in b -oxidation of
pristanoyl-CoA. Our data suggests a function for
ACOT6 in hydrolyzing in particular 2Rpristanoyl-CoA in white adipose tissue
peroxisomes to remove it from the b-oxidation
pathway, and the produced 2R-pristanic acid
may be esterified into triacylglycerols (which
may explain why pristanic acid accumulates in
white adipose tissue) or be b-oxidized in liver
following racemization.
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FIGURE LEGENDS
Figure 1. Peroxisomal a-oxidation, racemization and b-oxidation of branched fatty acids.
Phytanoyl-CoA undergoes a-oxidation to pristanoyl-CoA and the 2R stereoisomer must undergo
racemization to 2S-pristanoyl-CoA, which can be b-oxidized. Boxed enzymes are studied in this
paper.*The aldehyde dehydrogenase is argued to be localized either in peroxisomes or endoplasmic
reticulum.
Figure 2. ACOT6 is a peroxisomal protein. An Acot6/pcDNA3.1 NT-GFP construct was transfected
into human fibroblasts from a control subject (A) and a Zellweger patient (B) and localization was
detected by immunofluoresence microscopy using a Tritc-labeled anti-GFP antibody. The punctate
staining in control fibroblasts is abolished in the fibroblasts from the Zellweger patient, demonstrating
that ACOT6 is a peroxisomal protein.
Figure 3. Recombinant ACOT6 is highly active on pristanoyl-CoA. ACOT6 was expressed in the
pMAL-C2x vector as a fusion protein with maltose binding protein. Recombinant protein was purified
by affinity chromatography and acyl-CoA thioesterase activity was measured spectrophotometrically
in phosphate buffered saline (PBS) at 232 nm with various concentrations of pristanoyl-CoA. Vmax
and Km were calculated using the Prism Enzyme Kinetics software. The activity was measured in
duplicate on one protein preparation and data is shown as the mean activity.
Figure 4. ACOT6 is a specific phytanoyl-CoA/pristanoyl-CoA thioesterase. Acyl-CoA thioesterase
activity for pristanoyl-CoA (A) and phytanoyl-CoA (B) was measured in highly purified peroxisomes
from liver of control mice. Acyl-CoA thioesterase activity was measured spectrophotometrically in
PBS at 232 nm with various concentrations of phytanoyl-CoA and pristanoyl-CoA. Enzyme kinetics
were calculated using the Prism Enzyme Kinetics software. Activity measurements were carried out
in duplicate and data is shown as the mean activity.
(C) Immunoprecipitation of purified peroxisomes was carried out with an ACOT6 antibody, using
pre-immune serum as a control. Following immunoprecipitation, the remaining acyl-CoA thioesterase
activity was measured in the supernatants with 25 mM phytanoyl-CoA, pristanoyl-CoA or lauroylCoA in PBS at 232 nm and the specific activities were calculated. The experiment was performed
twice and data are shown ± range.
Figure 5. Peroxisomes contain the highest phytanoyl-CoA/pristanoyl-CoA thioesterase activity.
Subcellular fractionation of male mouse liver was performed and acyl-CoA thioesterase activity was
measured spectrophotometrically in PBS at 232 nm with 25mM phytanoyl-CoA and pristanoyl-CoA
and the specific activity was calculated. Cyt; cytosol, Mic; microsomes, Mito; mitochondria, Px;
peroxisomes. The subcellular fractionation was carried out on pooled livers and the activity
measurements were performed in duplicate and one representative experiment is shown.
Figure 6. Expression of Acot6 mRNA, protein and activity is increased via the peroxisome
proliferator-activated receptor alpha (PPARa). (A) Peroxisomes were prepared by subcellular
fractionation of pooled liver and kidney of control mice and mice fed 0.5% clofibrate in the diet for
one week. Acyl-CoA thioesterase activity was measured spectrophotometrically in duplicate with 25
mM of lauroyl-CoA, pristanoyl-CoA and phytanoyl-CoA and the specific activity was calculated for
each substrate. (B) Wild type (+/+) and PPARa-null (-/-) mice were fed either a standard chow diet or
a diet containing 0.1% Wy-14,643 for one week. Regulation of Acot6 expression was investigated at
mRNA level in liver by Q-PCR using Hprt1 as an endogenous control, and the relative expression
was calculated using the 2-DDCt method. The data are means ± S.E.M., n=3 (C) Western blotting was
carried out on 50 mg liver homogenates from wild type (+/+) and PPARa- null (-/-) mice using an
ACOT6 antibody.
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Figure 7. Acot6 and Acox3 are co-expressed in white adipose tissue. Tissue expression of Acot6
(A), Acox3 (B), Phyh (C), and Amacr (D) was investigated at mRNA level using Q-PCR in Sv129
male mice and an amplicon for Hprt1 was used as an endogenous control. The 2-DDCt method was used
to calculate the expression levels and presented as percentage of the tissue with highest expression for
each gene. Real time PCR was carried out on two cDNA preparations and data are shown ± range.
Prox. I.; proximal intestine, Dist. I.; distal intestine, BAT; brown adipose tissue, and WAT; white
adipose tissue.
Figure 8. Relative expression of Acot6, Amacr and Acox3 in various tissues. The expression levels
of Acot6, Amacr and Acox3 were compared by Q-PCR of the three amplicons in liver, kidney,
proximal intestine and white adipose tissue on the same plate using SYBRgreen for detection. An
amplicon for Hprt1 was used as an endogenous control and the 2-DDCt method was used to calculate the
expression levels that are presented as percentage of the Amacr expression in kidney (the gene with
highest expression). Prox. I.; proximal intestine and WAT; white adipose tissue. The data are the
means of triplicate determinations of each sample.
Figure 9. Putative functions for ACOT6 in the metabolism of branched fatty acids. Pristanic acid
may enter white adipose tissue (WAT) from the circulation, or be released from triglycerides (TG’s)
as a result of lipolysis within WAT, and is present as both the 2R and 2S stereoisomer. Subsequent
metabolism of pristanic acid involves the activation to the CoA ester (pristanoyl-CoA), and three
cycles of b-oxidation to form dimethylnonanoyl-CoA (DMN-CoA). However, due to the
stereospecificity of ACOX3 for the 2S-stereoisomer, the racemization of the 2R to the 2S
stereoisomer by a-methyacyl-CoA racemace (AMACR) is required for complete b-oxidation of
pristanic acid. In WAT peroxisomes, the AMACR is expressed at very low levels, which would result
in accumulation of the 2R-pristanoyl-CoA. Therefore ACOT6 is required to hydrolyze the 2Rpristanoyl-CoA to 2R-pristanic acid, which may then either be esterified/reesterified into triglycerides
and stored in WAT, or alternatively be transported to the liver (or kidney). The 2R-pristanic acid can
then enter peroxisomes and be racemized to the 2S-isomer by AMACR, resulting in b-oxidation to
DMN-CoA. The figure also depicts a role for acyl-CoA thioesterase 5 or 8 (ACOT5 or ACOT8) in
hydrolysis of DMN-CoA to release free DMN for excretion, or the action of carnitine
octanoyltransferase (CROT) in the formation of DMN-carnitine, which would be transported to the
mitochondria for further oxidation. An alternative role for pristanic acid (or phytanic acid) is also in
gene regulation, acting as ligands for the PPARa and RXRa in the nucleus of liver or brown adipose
tissue.
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TABLE I. Sequences of SYBRgreen primers for mouse phytanoyl-CoA hydroxylase (Phyh), amethylacyl-CoA racemase (Amacr), acyl-CoA oxidase 3 (Acox3), acyl-CoA thioesterase 6 (Acot6)
and hypoxanthine guanine phosphoribosyl transferase (Hprt1) for Q-PCR.
Phyh

Fwd 5’- ACT GCC TTC TCC CCG AGA TT -3’
Rev 5’- TGG GTC CAG TGA AAC ACT CCA -3’

Amacr

Fwd 5’-CTA TTT GGC TTT ATC AGG CGT TC -3’
Rev 5’-TTC TCA CCG CTT CTG CCA AT-3’

Acox3

Fwd 5’- TTG AGA AGA TCT ATA GCC TGG AGA TTT -3’
Rev 5’- AGT TCG GTG AGA GCA AAACAG C -3’

Acot6

Fwd 5’- GGT GAA AAG GAC CTC TCG AAG TG -3’
Rev 5’- ATA GTC AAG GGC ATA TCC AAC AAC A -3’

Hprt1

Fwd 5’- GGT GAA AAG GAC CTC TCG AAG TG -3’
Rev 5’- ATA GTC AAG GGC ATA TCC AAC AAC A -3’
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